It is thus feasible that a p53-mediated process contributes to α-TOS-induced DR5 upregulation in MM cells, consistent with another report suggesting p53 activation as a mode of sensitisation of cancer cells towards TRAIL killing (Xie et al, 2001). This evidence concerns the gene TNFRSF10B and Miyoshi myopathy.